Shares of Replimune Group (REPL) are down on Thursday, and it's not just a random dip. The company is staring down a big moment: an FDA review decision coming up on Friday, April 10. Think of it as a high-stakes test for their skin cancer drug, and investors are getting a bit jittery ahead of the results.

RP1's Rocky Road with the Regulators

Here's the backstory. In October 2025, the FDA accepted a resubmission for Replimune's Biologics License Application (BLA) for RP1. This isn't a solo act—it's RP1 combined with nivolumab, aimed at treating advanced melanoma in patients who didn't respond well to an anti-PD-1 regimen. But this is a second chance. Back in June 2025, the FDA sent a Complete Response Letter, which is basically a polite way of saying "not yet." The agency wasn't convinced that the IGNYTE trial provided enough solid evidence of the drug's effectiveness. So, Replimune went back to the drawing board, tweaked things, and now we're waiting to see if the FDA likes the new version better.

When the FDA's Own Drama Affects Your Drug

Now, here's where it gets interesting. According to reports from August 2025, the FDA's top cancer drug regulator got involved late in the review process for Replimune's treatment. This move apparently played a key role in that initial rejection, even though some folks within the agency were rooting for it. It turns out the FDA was dealing with its own stuff—leadership changes, staff coming and going, internal issues—and Replimune kind of got caught in the crossfire. It's a reminder that drug approvals aren't just about the science; sometimes, office politics can sway the outcome too.

On the financial side, Replimune isn't running on fumes just yet. The company says it has $269.1 million in cash, cash equivalents, and short-term investments. That should keep the lights on into the first quarter of 2027, giving them some breathing room regardless of what the FDA decides.

What the Charts Are Saying (And It's Not Great)

Let's talk numbers. At $5.79, the stock is trading 20.7% below its 20-day simple moving average and 30.2% below its 100-day average. In plain English, that means it's been on a bit of a slide lately, struggling to pick up any positive momentum. The relative strength index (RSI) is sitting at 35.33, which is neutral but leaning toward bearish—think of it as a warning sign that selling pressure might stick around.

Then there's the MACD, or moving average convergence divergence. It's showing a bearish trend, with the MACD at -0.0632 and the signal line at -0.0458. That's technical speak for "the sellers might still be in charge." Traders are eyeing key levels: $6.00 as a resistance point where selling tends to kick in, and $4.50 as a support level where buyers might step up. Over the past year, the stock has dropped 19.49%, and it's currently hanging out near the middle of its 52-week range—not exactly a sign of strong direction.

Market data shows the stock's momentum is weak, with a score of 17.08, indicating it's underperforming compared to the broader market. In action, Replimune shares were down 3.99% at $5.65 as of Thursday's publication, according to market data.

So, what's next? All eyes are on that FDA decision. If it's a thumbs-up, we could see a bounce. If not, those technical weaknesses might get even more pronounced. Either way, it's a classic biotech rollercoaster—high risk, high reward, and a lot of waiting around for news.